Table 2. Rate of overall survival ADCs by patients' characteristics.

Variables	Categories	ADCs (n = 435)			P-value	CERVICAL CA (n = 34)			P-value	KAPOSI SARCOMA (n = 184)			P-value	NON HODGKIN LYMPHOMA (n = 217)			P-value
		1y	5y	10y		1y	5y	10y		1y	5y	10y		1y	5y	10y
Total		77.0±2.0	67.7±2.4	61.1±2.9		90.9±5.0	87.3±6.0	78.5±9.9		86.9±2.5	79.1±3.2	72.8±4.0		66.6±3.2	55.0±3.5	48.2±4.3
Gender					0.613				NE*				0.498				0.874
	Male	77.8±2.3	66.7±2.7	60.5±3.2		-	-	-		87.7±2.6	79.2±3.3	73.5±4.1		66.9±3.6	54.6±4.0	47.4±4.9
	Female	76.8±4.5	71.7±4.9	63.8±6.1		90.9±5.0	87.3±6.0	78.5±9.9		76.9±11.7	76.9±11.7	65.9±14.3		65.1±7.6	57.0±8.0	51.3±9.0
Age, years					0.372				0.751				0.911				0.619
	18–34	82.4±4.3	76.2±5.0	65.1±6.7		100	100	66.7±2.7		89.6±4.9	83.7±6.1	69.6±9.0		67.1±8.5	57.8±9.7	57.8±9.7
	35–49	74.9±2.8	65.7±3.1	59.8±3.7		85.7±7.6	80.4±8.8	80.4±8.8		84.7±3.8	76.0±4.6	73.6±5.0		66.4±4.0	56.1±4.4	46.4±5.5
	50-max	77.8±4.3	65.6±5.1	61.5±6.2		100	-	-		89.0±4.6	81.5±6.0	74.1±8.9		66.7±6.8	49.7±7.6	49.7±7.6
IDVU					<0.001				0.060				0.002				0.276
	No	80.7±2.3	73.2±2.7	67.7±3.5		91.3±5.9	91.3±5.9	73.0±17.0		90.0±2.5	83.4±3.3	77.8±4.4		68.0±4.2	58.1±4.7	54.6±5.5
	Yes	69.3±3.9	56.4±4.3	48.6±4.8		90.0±9.5	80.0±12.6	80.0±12.6		74.8±7.3	62.5±8.3	53.8±9.1		64.7±5.0	51.4±5.4	42.0±6.2
AIDS event					0.024				0.273				0.162				0.022
	No	79.0±2.6	73.4±2.9	65.4±4.0		90.5±6.4	90.5±6.4	90.5±6.4		88.8±3.3	86.3±3.7	74.8±6.3		70.5±4.0	61.8±4.3	55.5±5.8
	Yes	74.3±3.3	60.4±3.8	55.2±4.1		91.7±8.0	81.5±11.9	61.1±19.8		85.0±3.8	72.2±5.0	70.2±5.2		60.2±5.5	44.4±5.8	37.8±6.1
Coinfection					0.075				0.957				0.129				0.895
	No	78.6±2.6	70.8±3.0	67.4±3.5		85.7±9.3	85.7±9.3	85.7±9.3		88.8±2.8	82.1±3.6	76.5±4.6		65.5±4.7	55.5±5.0	55.5±5.0
	Yes	75.0±3.2	63.61±3.7	53.7±4.5		94.7±5.1	88.8±7.5	76.1±13.4		82.8±5.2	72.5±6.3	64.7±7.7		67.7±4.5	54.8±5.0	44.2±6.0
cART					0.001				0.660				0.007				0.024
	No	63.7±5.5	51.7±5.9	49.6±6.0		90.0±9.5	90.0±9.5	90.0±9.5		67.4±9.5	58.9±10.0	58.9±10.0		55.5±7.7	39.2±7.8	35.9±7.8
	Yes	80.0±2.2	71.3±2.5	63.6±3.2		91.3±5.9	86.5±7.3	74.1±13.0		90.0±2.4	82.4±3.2	75.0±4.3		69.4±3.5	59.3±3.9	51.7±4.9
CD4+ count, cell/mm3					<0.001				0.003				0.001				0.001
	200-max	84.3±2.6	76.6±3.2	70.6±4.2		96.1±3.8	96.1±3.8	96.1±3.8		94.1±2.9	89.6±4.1	86.2±5.2		74.6±4.3	62.9±5.0	53.2±6.9
	0–199	64.3±3.6	53.7±3.9	49.3±4.1		71.4±17.1	57.1±18.7	42.9±18.7		78.8±4.6	69.1±5.3	64.3±5.9		50.8±5.4	39.5±5.3	36.9±5.6
Nadir CD4+ count, cell/mm3					<0.001				0.085				0.001				0.033
	≥200	87.4±3.2	81.3±3.8	77.9±4.9		100	100	100		97.9±2.1	93.0±3.9	85.9±7.8		73.3±6.3	63.9±7.1	63.9±7.1
	50–199	69.3±3.5	77.7±3.1	61.4±4.4		75.0±15.3	62.5±17.1	62.5±17.1		88.8±3.7	84.0±4.5	75.6±6.1		69.8±4.6	59.2±5.1	49.9±6.6
	<50	67.5±4.1	54.5±4.5	48.8±4.9		90.0±9.5	90.0±9.5	90.0±9.5		75.5±5.7	61.9±6.6	58.8±7.0		56.8±6.2	42.8±6.3	37.1±6.8
HIVRNA, copies/mL					0.020				0.841				0.015				0.032
	Undetectable	84.8±3.5	77.8±4.3	72.6±5.3		91.7±7.9	91.7±7.9	61.1±25.5		97.6±2.3	91.2±5.0	86.1±6.8		73.2±6.1	64.4±6.8	64.4±6.8
	Positive	70.8±2.8	60.0±3.2	54.8±3.6		90.5±6.4	84.8±8.1	84.8±8.1		80.4±3.9	71.7±4.6	67.5±5.2		60.2±4.2	47.1±4.5	40.2±5.1

Note: Plus minus are value standard error, P value are from long rank test. - The sample size was too small for Kaplan Meier analysis.

*NE, not evaluable. ADCs: AIDS-defining cancers, IVDU: Intravenous Drug Use, cART: combined antiretroviral therapy; CA: cancer.